NVIV Annual EBITDA
-$10.21 M
-$677.00 K-7.11%
31 December 2022
Summary:
As of January 22, 2025, NVIV annual earnings before interest, taxes, depreciation & amortization is -$10.21 million, with the most recent change of -$677.00 thousand (-7.11%) on December 31, 2022. During the last 3 years, it has risen by +$970.00 thousand (+8.68%).NVIV EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
NVIV Quarterly EBITDA
-$2.76 M
-$782.00 K-39.61%
30 September 2023
Summary:
As of January 22, 2025, NVIV quarterly earnings before interest, taxes, depreciation & amortization is -$2.76 million, with the most recent change of -$782.00 thousand (-39.61%) on September 30, 2023. Over the past year, it has dropped by -$66.00 thousand (-2.45%).NVIV Quarterly EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
NVIV TTM EBITDA
-$9.44 M
-$66.00 K-0.70%
30 September 2023
Summary:
As of January 22, 2025, NVIV TTM earnings before interest, taxes, depreciation & amortization is -$9.44 million, with the most recent change of -$66.00 thousand (-0.70%) on September 30, 2023. Over the past year, it has increased by +$1.25 million (+11.67%).NVIV TTM EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
NVIV EBITDA Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -7.1% | -2.5% | +11.7% |
| 3 y3 years | +8.7% | -25.2% | -1.2% |
| 5 y5 years | +57.8% | -31.5% | +15.6% |
NVIV EBITDA High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | ||||||
| 5 y | 5-year | ||||||
| alltime | all time | -300.0% | -133.8% | -284.9% |
InVivo Therapeutics Holdings EBITDA History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2023 | - | -$2.76 M(+39.6%) | -$9.44 M(+0.7%) |
| June 2023 | - | -$1.97 M(-16.7%) | -$9.37 M(-6.5%) |
| Mar 2023 | - | -$2.37 M(+1.4%) | -$10.02 M(-1.8%) |
| Dec 2022 | -$10.21 M(+7.1%) | -$2.34 M(-13.1%) | -$10.21 M(-4.5%) |
| Sept 2022 | - | -$2.69 M(+2.6%) | -$10.68 M(+3.2%) |
| June 2022 | - | -$2.62 M(+2.5%) | -$10.35 M(+4.0%) |
| Mar 2022 | - | -$2.56 M(-9.2%) | -$9.95 M(+4.4%) |
| Dec 2021 | -$9.53 M(+8.7%) | -$2.81 M(+19.4%) | -$9.53 M(+8.1%) |
| Sept 2021 | - | -$2.36 M(+6.2%) | -$8.82 M(+1.8%) |
| June 2021 | - | -$2.22 M(+4.0%) | -$8.66 M(+1.3%) |
| Mar 2021 | - | -$2.13 M(+1.4%) | -$8.55 M(-2.4%) |
| Dec 2020 | -$8.77 M(-21.5%) | -$2.10 M(-4.4%) | -$8.77 M(-5.9%) |
| Sept 2020 | - | -$2.20 M(+4.2%) | -$9.32 M(-4.6%) |
| June 2020 | - | -$2.11 M(-10.0%) | -$9.77 M(-9.7%) |
| Mar 2020 | - | -$2.35 M(-11.7%) | -$10.83 M(-3.1%) |
| Dec 2019 | -$11.18 M(-11.8%) | -$2.66 M(+0.2%) | -$11.18 M(-2.9%) |
| Sept 2019 | - | -$2.65 M(-16.2%) | -$11.51 M(+5.1%) |
| June 2019 | - | -$3.17 M(+17.4%) | -$10.95 M(+3.5%) |
| Mar 2019 | - | -$2.70 M(-9.9%) | -$10.58 M(-16.5%) |
| Dec 2018 | -$12.68 M(-47.6%) | -$2.99 M(+42.8%) | -$12.68 M(-11.7%) |
| Sept 2018 | - | -$2.10 M(-25.0%) | -$14.36 M(-22.2%) |
| June 2018 | - | -$2.79 M(-41.7%) | -$18.45 M(-17.8%) |
| Mar 2018 | - | -$4.79 M(+2.5%) | -$22.46 M(-7.2%) |
| Dec 2017 | -$24.20 M(+6.4%) | -$4.67 M(-24.5%) | -$24.20 M(-2.4%) |
| Sept 2017 | - | -$6.19 M(-8.9%) | -$24.79 M(+0.7%) |
| June 2017 | - | -$6.80 M(+4.0%) | -$24.63 M(+7.8%) |
| Mar 2017 | - | -$6.53 M(+24.1%) | -$22.85 M(+0.5%) |
| Dec 2016 | -$22.73 M(-30.0%) | -$5.26 M(-12.7%) | -$22.73 M(+3.5%) |
| Sept 2016 | - | -$6.03 M(+20.2%) | -$21.96 M(+21.8%) |
| June 2016 | - | -$5.02 M(-21.8%) | -$18.03 M(-22.4%) |
| Mar 2016 | - | -$6.41 M(+42.5%) | -$23.25 M(-28.4%) |
| Dec 2015 | -$32.46 M(+85.9%) | -$4.50 M(+114.2%) | -$32.46 M(-10.1%) |
| Sept 2015 | - | -$2.10 M(-79.5%) | -$36.12 M(+3.2%) |
| June 2015 | - | -$10.24 M(-34.5%) | -$35.01 M(+24.1%) |
| Mar 2015 | - | -$15.62 M(+91.2%) | -$28.20 M(+61.5%) |
| Dec 2014 | -$17.46 M | -$8.17 M(+726.6%) | -$17.46 M(+18.2%) |
| Sept 2014 | - | -$988.00 K(-71.2%) | -$14.77 M(-22.2%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| June 2014 | - | -$3.43 M(-29.7%) | -$18.99 M(-35.9%) |
| Mar 2014 | - | -$4.88 M(-11.0%) | -$29.63 M(-21.8%) |
| Dec 2013 | -$37.89 M(-842.4%) | -$5.48 M(+5.1%) | -$37.89 M(-7.4%) |
| Sept 2013 | - | -$5.21 M(-63.0%) | -$40.93 M(+48.5%) |
| June 2013 | - | -$14.07 M(+7.1%) | -$27.56 M(+145.5%) |
| Mar 2013 | - | -$13.13 M(+54.0%) | -$11.22 M(-320.0%) |
| Dec 2012 | $5.10 M(-114.8%) | -$8.52 M(-204.4%) | $5.10 M(-134.2%) |
| Sept 2012 | - | $8.16 M(+260.3%) | -$14.90 M(-41.0%) |
| June 2012 | - | $2.27 M(-29.1%) | -$25.24 M(-15.9%) |
| Mar 2012 | - | $3.20 M(-111.2%) | -$30.00 M(-13.2%) |
| Dec 2011 | -$34.57 M(+373.5%) | -$28.53 M(+1212.2%) | -$34.57 M(+472.4%) |
| Sept 2011 | - | -$2.17 M(-12.8%) | -$6.04 M(+55.3%) |
| June 2011 | - | -$2.49 M(+81.6%) | -$3.89 M(+173.4%) |
| Mar 2011 | - | -$1.37 M(+5692.0%) | -$1.42 M(+2165.3%) |
| Dec 2010 | -$7.30 M(>+9900.0%) | - | - |
| Sept 2010 | - | -$23.70 K(-9.5%) | -$62.80 K(+31.4%) |
| June 2010 | - | -$26.20 K(+285.3%) | -$47.80 K(-14.8%) |
| Mar 2010 | - | -$6800.00(+11.5%) | -$56.10 K(-35.7%) |
| Mar 2010 | -$56.10 K(-13.0%) | - | - |
| Dec 2009 | - | -$6100.00(-29.9%) | -$87.30 K(+3.4%) |
| Sept 2009 | - | -$8700.00(-74.8%) | -$84.40 K(+16.3%) |
| June 2009 | - | -$34.50 K(-9.2%) | -$72.60 K(+24.5%) |
| Mar 2009 | -$64.50 K(+81.2%) | -$38.00 K(+1087.5%) | -$58.30 K(+24.8%) |
| Dec 2008 | - | -$3200.00(-203.2%) | -$46.70 K(-6.8%) |
| Sept 2008 | - | $3100.00(-115.3%) | -$50.10 K(-5.8%) |
| June 2008 | - | -$20.20 K(-23.5%) | -$53.20 K(+43.0%) |
| Mar 2008 | -$35.60 K(-92.1%) | -$26.40 K(+300.0%) | -$37.20 K(-89.6%) |
| Dec 2007 | - | -$6600.00(<-9900.0%) | -$358.10 K(-7.0%) |
| Sept 2007 | - | $0.00(-100.0%) | -$384.90 K(-11.5%) |
| June 2007 | - | -$4200.00(-98.8%) | -$434.70 K(-3.4%) |
| Mar 2007 | -$449.90 K(+1219.4%) | -$347.30 K(+939.8%) | -$449.90 K(+263.4%) |
| Dec 2006 | - | -$33.40 K(-32.9%) | -$123.80 K(+29.6%) |
| Sept 2006 | - | -$49.80 K(+156.7%) | -$95.50 K(+87.6%) |
| June 2006 | - | -$19.40 K(-8.5%) | -$50.90 K(+61.6%) |
| Mar 2006 | -$34.10 K | -$21.20 K(+315.7%) | -$31.50 K(+205.8%) |
| Dec 2005 | - | -$5100.00(-1.9%) | -$10.30 K(+98.1%) |
| Sept 2005 | - | -$5200.00 | -$5200.00 |
FAQ
- What is InVivo Therapeutics Holdings annual earnings before interest, taxes, depreciation & amortization?
- What is the all time high annual EBITDA for InVivo Therapeutics Holdings?
- What is InVivo Therapeutics Holdings annual EBITDA year-on-year change?
- What is InVivo Therapeutics Holdings quarterly earnings before interest, taxes, depreciation & amortization?
- What is the all time high quarterly EBITDA for InVivo Therapeutics Holdings?
- What is InVivo Therapeutics Holdings quarterly EBITDA year-on-year change?
- What is InVivo Therapeutics Holdings TTM earnings before interest, taxes, depreciation & amortization?
- What is the all time high TTM EBITDA for InVivo Therapeutics Holdings?
- What is InVivo Therapeutics Holdings TTM EBITDA year-on-year change?
What is InVivo Therapeutics Holdings annual earnings before interest, taxes, depreciation & amortization?
The current annual EBITDA of NVIV is -$10.21 M
What is the all time high annual EBITDA for InVivo Therapeutics Holdings?
InVivo Therapeutics Holdings all-time high annual earnings before interest, taxes, depreciation & amortization is $5.10 M
What is InVivo Therapeutics Holdings annual EBITDA year-on-year change?
Over the past year, NVIV annual earnings before interest, taxes, depreciation & amortization has changed by -$677.00 K (-7.11%)
What is InVivo Therapeutics Holdings quarterly earnings before interest, taxes, depreciation & amortization?
The current quarterly EBITDA of NVIV is -$2.76 M
What is the all time high quarterly EBITDA for InVivo Therapeutics Holdings?
InVivo Therapeutics Holdings all-time high quarterly earnings before interest, taxes, depreciation & amortization is $8.16 M
What is InVivo Therapeutics Holdings quarterly EBITDA year-on-year change?
Over the past year, NVIV quarterly earnings before interest, taxes, depreciation & amortization has changed by -$66.00 K (-2.45%)
What is InVivo Therapeutics Holdings TTM earnings before interest, taxes, depreciation & amortization?
The current TTM EBITDA of NVIV is -$9.44 M
What is the all time high TTM EBITDA for InVivo Therapeutics Holdings?
InVivo Therapeutics Holdings all-time high TTM earnings before interest, taxes, depreciation & amortization is $5.10 M
What is InVivo Therapeutics Holdings TTM EBITDA year-on-year change?
Over the past year, NVIV TTM earnings before interest, taxes, depreciation & amortization has changed by +$1.25 M (+11.67%)